The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The Use of Human Hepatocytes to Select Compounds Based on Their Expected Hepatic Extraction Ratios in Humans
Abstract
Purpose The present investigation retrospectively evaluates the use of human hepatocytes to classify compounds into low, intermediate or high hepatic extraction ratio in man. Methods A simple approach was used to correlate the in vivo hepatic extraction ratio of a number of compounds in man (literature and in-house data) with the corresponding in vitro clearance which was determined in human hepatocytes. The present approach assumes that, for compounds eliminated mainly through liver metabolism, intrinsic clearance is the major determinant for their in vivo hepatic extraction ratio and subsequently their bioavailability in man. The test compounds were selected to represent a broad range of extraction ratios and a variety of metabolic pathways. Results The present data show that in vitro clearances in human hepatocytes are predictive for the hepatic extraction ratios in vivo in man. Most of the test compounds (n = 19) were successfully classified based upon human hepatocyte data into low, intermediate or high hepatic extraction compounds, i.e. compounds with potential for high, intermediate or low bioavailabilities in humans. Conclusions The present approach, validated so far with 19 test compounds, appears to be a valuable tool to screen for compounds with respect to liver first-pass metabolism at an early phase of drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this method, no protein binding was considered, resulting in overestimation of ERH,pred values of highly bound drugs.”
From Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling (2019) · cites this paper as [61]
In the citing paper
“Another empirical analysis was performed by Lavé et al. [61], who used human hepatocytes as an in vitro system to predict human ERH.”
From Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling (2019) · cites this paper as [61]
Citations
Cites
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925
Clinical Pharmacokinetics and Pharmacodynamics of Warfarin
Holford, N. H. G. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611060-00005 · Cited by 362
Pharmacokinetics and bioavailability of midazolam in man.
Heizmann, P., Eckert, M., & Ziegler, W. H. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb02270.x · Cited by 295
Allonen, H. O., Ziegler, G., & Klotz, U. E. (1981) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1981.217 · Cited by 288
The pharmacokinetics of midazolam in man
Smith, M. T., Eadie, M. J., & Brophy, T. (1981) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562804 · Cited by 277
Clinical Importance of Hepatic Cytochrome P450 in Drug Metabolism
Spatzenegger, M., & Jaeger, W. (1995) · Drug Metabolism Reviews · doi:10.3109/03602539508998329 · Cited by 247
Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.
Klotz, U. E., Antonin, K. H., & Bieck, P. R. (1976) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30657-9 · Cited by 213
Interspecies Comparison of In Vivo Caffeine Pharmacokinetics in Man, Monkey, Rabbit, Rat and Mouse
Bonati, M. R., Latini, R., Tognoni, G., Young, J. F., & Garattini, S. K. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409029964 · Cited by 171
Fabre, G., Rahmani, R., Placidi, M., Combalbert, J., Covo, J., Cano, J. P., Coulange, C., Ducros, M., & Rampal, M. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90622-3 · Cited by 96
Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog
Seddon, T., Michelle, I., & Chenery, R. J. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90314-6 · Cited by 67
Stereoselective clearance and distribution of intravenous propranolol
Olanoff, L. S., Walle, T., Walle, U. K., Cowart, T. D., & Gaffney, T. E. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.107 · Cited by 62
Kawasaki, S., Sugiyama, Y., Iga, T., Hanano, M., Beppu, T., Sugiura, M., Sanjo, K., & Idezuki, Y. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.140 · Cited by 58
In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data.
Hayes, K. A., Brennan, B. S., Chenery, R. J., & Houston, J. B. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06544-4 · Cited by 56
Bioavailability and pharmacokinetics of oxazepam
Sonne, J., Loft, S. H., D�ssing, M., Vollmer-Larsen, A., Olesen, K. L., Victor, M., Andreasen, F., & Andreasen, P. B. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf00561369 · Cited by 52
Predicting the hepatic clearance of xenobiotics in humans from in vitro data
Hoener, B. (1994) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510150404 · Cited by 51
Zomorodi, K., Carlile, D. J., & Houston, J. B. (1995) · Xenobiotica · doi:10.3109/00498259509046662 · Cited by 47
Skett, P., Tyson, C., Guillouzo, A., & Maier, P. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)90011-x · Cited by 41
Comparative pharmacokinetics of benzodiazepines in dog and man
Boxenbaum, H. (1982) · Journal of pharmacokinetics and biopharmaceutics · doi:10.1007/bf01065172 · Cited by 39
Clinical Pharmacokinetics and Efficacy of Renin Inhibitors
Rongen, G. A. P. J. M., Lenders, J. W. M., Smits, P., & Thien, T. A. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529010-00002 · Cited by 37
Interspecies Metabolism and Pharmacokinetic Scaling of Theophylline Disposition
Gaspari, F., & Bonati, M. R. (1990) · Drug Metabolism Reviews · doi:10.3109/03602539009041084 · Cited by 30
de Sousa, G., Florence, N., Vallès, B., Coassolo, P., & Rahmani, R. (1995) · Cell Biology and Toxicology · doi:10.1007/bf00756516 · Cited by 21
Self-citationPhysiological Disposition of Intravenously Administered 14C-Labeled Diltiazem in Healthy Volunteers
Höglund, P., & Nilsson, L. (1988) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198804000-00006 · Cited by 10
Flagged first, then by citations
Cited by
Sorted by citations
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
Predicting the Impact of Physiological and Biochemical Processes on Oral Drug Bioavailability
Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00179-x · Cited by 651
Riley, R. J., McGinnity, D. F., & Austin, R. P. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004259 · Cited by 382
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
Jones, H. M., Parrott, N., Jorga, K., & Lav??, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00006 · Cited by 352
Metadata
- Authors
- Lavé, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R. C., Jaeck, D., & Coassolo, P.
- ORCID
- Schmitt, C.
- Venue
- Pharmaceutical Research
- Published
- 1997-02
- Volume
- 14
- Issue
- 2
- Pages
- 152-155
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1264367399
- Cited by
- 106
- References
- 22
- Citations by year
- 2026: 1 · 2024: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 9 · 2015: 7 · 2014: 2 · 2013: 5 · 2012: 2
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- human hepatocytes, hepatic extraction ratio, intrinsic clearance, in vitro-in vivo correlation, bioavailability prediction, first-pass metabolism, drug discovery screening, hepatic metabolism, compound classification
- MeSH terms
- Adult, Aged, Biological Availability, Cells, Cultured, Drug Evaluation, Preclinical, Pharmaceutical Preparations, Humans, Liver, Metabolic Clearance Rate, Middle Aged, Pharmacokinetics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
